Praxis Precision Medicines — Third Quarter 2026 Earnings Summary

Praxis Precision Medicines reported a net loss of $94.2 million for the third quarter of 2026, with cash and investments totaling approximately $1.3 billion as of September 30, 2026. The company's New Drug Applications for relutrigine and ulixacaltamide remain under FDA review, with target action dates set for December 27, 2026, and January 29, 2027, respectively. Commercial launch preparations are advancing for both candidates, including the full hiring of the relutrigine team and the expected completion of the ulixacaltamide sales force in the fourth quarter of 2026. Additionally, the EMERALD study for relutrigine is nearing completion with topline results anticipated in the fourth quarter of 2026, while the EMBRAVE3 trial for elsunersen is progressing toward results in 2027.